Patients
ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee
A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
Sales & Marketing
The hidden benefits of Chat LLMs on publisher sites
As AI chat interfaces become the first point of interaction for HCP queries, a new kind of inventory is emerging.
Digital
Nordic Global on improving NHS patient outcomes with tech & ...
Nordic Global is helping NHS organisations transform patient access through digital transformation.
R&D
Purespring on nephrology & gene therapy in kidney disease
Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.
Digital
The cliff was never the crisis: Pharma’s strategy problem
The patent cliff isn't the problem. It's the symptom.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
